PTC Therapeutics Stock Jumps After $2 Billion Novartis Deal
Key Highlights:
PTC Therapeutics' stock surged 16% after announcing a major licensing deal with Novartis.
The deal grants Novartis global rights to develop, manufacture, and commercialize PTC’s Huntington’s Disease drug, PTC518.
PTC will receive $1 billion upfront, with the potential to earn up to $1.9 billion in total milestone payments.
Shares of PTC Therapeutics (PTCT) climbed sharply on Monday after the company announced a collaboration agreement with Novartis (NVS) worth nearly $2 billion.
The agreement allows Novartis to take over global responsibilities for PTC518, an experimental treatment for Huntington’s Disease, after the completion of an ongoing Phase 2 study.
Deal Breakdown
Upfront Payment: PTC will receive $1 billion immediately.
Milestone Payments: Up to $1.9 billion in development, regulatory, and sales milestones.
Profit Sharing: In the U.S., Novartis will take 60% of profits while PTC gets 40%.
Royalties: PTC will earn double-digit tiered royalties on sales outside the U.S.
PTC’s CEO, Dr. Matthew Klein, stated that the funds would be used to expand the company’s splicing platform and strengthen its commercial and development efforts.
Market Impact
The announcement pushed PTC’s stock to its highest level since May 2023, reflecting investor optimism about the deal’s potential. Meanwhile, Novartis’ American depositary receipts (ADRs) dipped slightly, down about 1%.
The transaction is expected to finalize in the first quarter of 2025, marking a significant step for PTC in its mission to advance innovative treatments.
Key Highlights:
PTC Therapeutics' stock surged 16% after announcing a major licensing deal with Novartis.
The deal grants Novartis global rights to develop, manufacture, and commercialize PTC’s Huntington’s Disease drug, PTC518.
PTC will receive $1 billion upfront, with the potential to earn up to $1.9 billion in total milestone payments.
Shares of PTC Therapeutics (PTCT) climbed sharply on Monday after the company announced a collaboration agreement with Novartis (NVS) worth nearly $2 billion.
The agreement allows Novartis to take over global responsibilities for PTC518, an experimental treatment for Huntington’s Disease, after the completion of an ongoing Phase 2 study.
Deal Breakdown
Upfront Payment: PTC will receive $1 billion immediately.
Milestone Payments: Up to $1.9 billion in development, regulatory, and sales milestones.
Profit Sharing: In the U.S., Novartis will take 60% of profits while PTC gets 40%.
Royalties: PTC will earn double-digit tiered royalties on sales outside the U.S.
PTC’s CEO, Dr. Matthew Klein, stated that the funds would be used to expand the company’s splicing platform and strengthen its commercial and development efforts.
Market Impact
The announcement pushed PTC’s stock to its highest level since May 2023, reflecting investor optimism about the deal’s potential. Meanwhile, Novartis’ American depositary receipts (ADRs) dipped slightly, down about 1%.
The transaction is expected to finalize in the first quarter of 2025, marking a significant step for PTC in its mission to advance innovative treatments.